{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:25:41Z","timestamp":1789475141518,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s43441-022-00390-4","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T14:33:48Z","timestamp":1648046028000},"page":"501-516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2474-6811","authenticated-orcid":false,"given":"Deli","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7915-877X","authenticated-orcid":false,"given":"Elaine Kearney","family":"Kowalewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"390_CR1","volume-title":"World Alzheimer Report 2021: Journey Through the Diagnosis of Dementia","author":"S Gauthier","year":"2021","unstructured":"Gauthier S, Rosa-Neto P, Morais J, Webster C. World Alzheimer Report 2021: Journey Through the Diagnosis of Dementia. London: Alzheimer\u2019s Disease International; 2021."},{"key":"390_CR2","doi-asserted-by":"crossref","unstructured":"2021 Alzheimer's disease facts and figures. Alzheimer\u2019s & Dement. 2021;17(3):327\u2013406.","DOI":"10.1002\/alz.12328"},{"key":"390_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-017-0283-5","volume":"9","author":"PS Aisen","year":"2017","unstructured":"Aisen PS, Cummings JL, Jack CR, Morris JC, Sperling RA, Froelich L, et al. On the path to 2025: understanding the Alzheimer\u2019s disease continuum. Alzheimer\u2019s Res Ther. 2017;9:1.","journal-title":"Alzheimer's Res Ther"},{"issue":"3","key":"390_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer's & Dement. 2011;7(3):280\u201392.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"390_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8(6):595\u2013608.","journal-title":"EMBO Mol Med"},{"issue":"7618","key":"390_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature"},{"key":"390_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimer\u2019s Res Ther. 2021. https:\/\/doi.org\/10.1186\/s13195-021-00813-8.","journal-title":"Alzheimer's Res Ther"},{"issue":"18","key":"390_CR8","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704.","journal-title":"N Engl J Med"},{"key":"390_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0318-y","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2017. https:\/\/doi.org\/10.1186\/s13195-017-0318-y.","journal-title":"Alzheimer's Res Ther"},{"key":"390_CR10","unstructured":"FDA\u2019s Decision to Approve New Treatment for Alzheimer\u2019s Disease [Press Release]. U.S. Food & Drug Administration, June 7 2021 https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fdas-decision-approve-new-treatment-alzheimers-disease."},{"key":"390_CR11","unstructured":"Nuance Communications, Inc. 1995\u20132018. Nuance Power PDF Advanced(C) Software Version 3.0. Nuance Communications, Inc."},{"issue":"4","key":"390_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/sim.1040","volume":"21","author":"HC Van Houwelingen","year":"2002","unstructured":"Van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002;21(4):589\u2013624.","journal-title":"Stat Med"},{"key":"390_CR13","volume-title":"SAS\/STAT(R): 15.1 User\u2019s Guide","author":"SAS Institute Inc","year":"2018","unstructured":"SAS Institute Inc. SAS\/STAT(R): 15.1 User\u2019s Guide. Cary: SAS Institute Inc; 2018."},{"key":"390_CR14","unstructured":"A study of donanemab (LY3002813) in participants with early Alzheimer's disease (TRAILBLAZER-ALZ 2). https:\/\/ClinicalTrials.gov\/show\/NCT04437511."},{"key":"390_CR15","unstructured":"A study to confirm safety and efficacy of lecanemab in participants with early Alzheimer's disease. https:\/\/ClinicalTrials.gov\/show\/NCT03887455."},{"key":"390_CR16","unstructured":"Safety and efficacy study of gantenerumab in participants with early Alzheimer's disease (AD). https:\/\/ClinicalTrials.gov\/show\/NCT03443973."},{"key":"390_CR17","unstructured":"Efficacy and safety study of gantenerumab in participants with early Alzheimer's disease (AD). https:\/\/ClinicalTrials.gov\/show\/NCT03444870."},{"key":"390_CR18","unstructured":"Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee Meeting Announcement: Hearing before the US Food & Drug Administration (November 11, 2020) https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/november-6-2020-meeting-peripheral-and-central-nervous-system-drugs-advisory-committee-meeting."},{"key":"390_CR19","doi-asserted-by":"publisher","first-page":"P1668","DOI":"10.1016\/j.jalz.2018.07.009","volume":"14","author":"C Swanson","year":"2018","unstructured":"Swanson C, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai R, et al. Treatment of early AD subjects with BAN2401, an anti-A\u03b2 protofibril monoclonal antibody, significantly clears amyloid plaque and reduces clinical decline. Alzheimer\u2019s & Dement. 2018;14:1668.","journal-title":"Alzheimers Dement"},{"key":"390_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0559-z","author":"G Klein","year":"2019","unstructured":"Klein G, Delmar P, Voyle N, Rehal S, Hofmann C, Abi-Saab D, et al. Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: a PET substudy interim analysis. Alzheimer\u2019s Res Ther. 2019. https:\/\/doi.org\/10.1186\/s13195-019-0559-z.","journal-title":"Alzheimer's Res Ther"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-022-00390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-022-00390-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-022-00390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T17:25:02Z","timestamp":1648574702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-022-00390-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["390"],"URL":"https:\/\/doi.org\/10.1007\/s43441-022-00390-4","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,23]]},"assertion":[{"value":"7 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest. Nevertheless, the authors acknowledge that AbbVie has an Alzheimer's research program in the same drug class as the medicines in the clinical trials that are addressed by the analyses in this manuscript. In addition, as the manuscript indicates, the data structures and analyses that are necessary to support accelerated approval by a regulatory agency for a medicine for Alzheimer's disease are beyond the scope of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}